Country for PR: China
Contributor: PR Newswire Asia (China)
Monday, July 04 2022 - 21:30
JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular Carcinoma
SHANGHAI, July 4, 2022 /PRNewswire-AsiaNet/ --

JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology 
company focusing on developing, manufacturing and commercializing cell 
immunotherapy products, announced the initiation of phase I clinical study of 
JWATM204 in patients with advanced hepatocellular carcinoma (HCC).

Primary liver cancer (PLC), also known as liver carcinoma, is one of the common 
gastrointestinal malignancies worldwide. Approximately 85%-90% of liver cancers 
were hepatocellular carcinoma (HCC). GLOBOCAN survey in 2020 found that 906 
thousands of new cases were diagnosed and 830 thousand deaths world-wide each 
year, which took the sixth position out of malignancies and the 3rd leading 
cause of cancer death1. The 5-year survival rate was 15%-19% in North America. 
The disease burden of liver cancer was particularly high in China. Liver cancer 
was the 4th most common malignancies, the 2nd leading cause of cancer deaths, 
and the 5-year survival rate was only 12.1% in China. The ratio of 1:0.9 
between the incidence and mortality indicated the poor prognosis of liver 
cancer, which seriously threatened the lives and health of the Chinese 
population,[1],[2],. In recent years, immunotherapies represented by immune 
checkpoint inhibitors have achieved Overall Response Rates (ORRs) of 17%-20% 
and 15%-20% for the first- and second- line therapies respectively in HCC 
patients. Nevertheless, there are still challenges including post-treatment 
disease progression and alternative regimens in response to relapse.

This first-in-human study of JWATM204 aims to evaluate the safety, 
tolerability, dose limited toxicity and pharmacokinetic profile of JWATM204 in 
adult subjects with advanced HCC, and also to explore the anti-tumor activity 
of JWATM204 in the target population. The promising preclinical results showed 
continued clinical development potential of JWATM204 for the treatment of HCC.

JWATM204, with high affinity and specificity of GPC-3 monoclonal antibody and 
developed at the ARTEMIS® T-cell platform, is an innovative immune T-cell 
therapy targeting glypican-3 (GPC-3). JW Therapeutics in-licensed the rights 
from Eureka to develop, manufacture and commercialize JWATM204 in China 
(including mainland China, Hong Kong, Macao and Taiwan) and the member 
countries of the Association of Southeast Asian Nations in 2020, and has 
completed technical transfer and renovation of facilities and equipment at 
Shanghai Waigaoqiao manufacturing site.

James Li, Co-founder, Chairman and CEO of JW Therapeutics, said, "Solid tumors 
are a critical part of JW Therapeutics' product pipeline strategy. Leveraging 
our platform for technology and product development, we are now developing 
breakthrough cell immunotherapy products to address the solid tumor with high 
incidence in China, and advancing the pipeline products to clinical studies."


1.  Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel, et al. Global Cancer 
Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 
Cancers in 185 Countries. ACS journals. 2021, 71(3):209-249

About JWATM204

JWATM204, with the high affinity and specificity of GPC-3 monoclonal antibody 
developed at the ARTEMIS® T-cell platform, is an innovative immune T-cell 
therapy targeting GPC-3. GPC-3, a member of the glypican-related integral 
membrane proteoglycan family, is overexpressed in multiple malignancies 
including HCC, but not or lowly expressed in normal organs, including normal 
liver organs or cirrhosis liver. GPC-3 is expressed in 72% of HHC patients1. 
GPC-3 holds its oncogenic effect through Wnt pathway2. GPC-3 has become a 
popular target for HCC due to its high sensitivity and specificity. The 
ARTEMIS® T cell platform, with intracellular regulatory mechanism similar to 
TCR-T cell therapy and precision of CAR-T therapy, is expected to significantly 
reduce or even eliminate cytokine release syndrome (CRS) associated with T cell 
over activation and other life-threatening cytokine-related toxicities. With 
the assistance of co-stimulatory molecules on the surface of T cells, 
sufficient T cell activation signals can be generated, which can promote T cell 
activation and strengthen the antitumor activity.


1.  Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and 
histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003; 
2.  Kolluri A and Ho M. The Role of Glypican-3 in Regulating Wnt, YAP, and 
Hedgehog in Liver Cancer. Front. Oncol. 2019, 9:708.

About JW Therapeutics

JW Therapeutics (HKEX: 2126) is an independent and innovative biotechnology 
company focusing on developing, manufacturing and commercializing cell 
immunotherapy products, and is committed to becoming an innovation leader in 
cell immunotherapy. Founded in 2016, JW Therapeutics has built a world-class 
platform for product development in cell immunotherapy, as well as a product 
pipeline covering both hematologic malignancies and solid tumors. JW 
Therapeutics is committed to bringing breakthrough and quality cell 
immunotherapy products and the hope of a cure to patients in China and 
worldwide, and leading the healthy and standardized development of China's cell 
immunotherapy industry. For more information, please visit

Forward-Looking Statements

The forward-looking statements are based on the management's expectations and 
beliefs and are subject to a number of risks and uncertainties that could cause 
actual results to differ materially from those described. Significant risks and 
uncertainties, include those discussed below and more fully described in Hong 
Kong Exchanges and Clearing Limited (HKEX) reports filed by the Company. Unless 
otherwise noted, the Company is providing this information as of the date it 
publicized, and expressly disclaims any duty to update information contained in 
the issues and relevant information, or provide any explanation. For detailed 
information, please visit the company website:

[1] ALLEMANI C, WEIR HK, CARREIRA H, et al. Global surveillance of cancer 
survival 1995-2009: analysis of individual data for 25, 676, 887 patients from 
279 population-based registries in 67countries (CONCORD-2) . Lancet, 2015, 385: 
[2] TORRE LA, BRAY F, SIEGEL RL, et al. Global cancer statistics, 2012. CA 
Cancer J Clin, 2015, 65: 87-108.

SOURCE: JW Therapeutics